SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused
on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases,
today announced that it intends to offer and sell 4,750,000
shares of its common stock in an underwritten public offering.
In addition, Audentes intends to grant the underwriters a
30-day option to purchase up to an additional 712,500 shares of
common stock. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running
managers for the offering. Wedbush PacGrow is acting as a
co-manager.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective.
The proposed offering is being made only by means of a
prospectus. A copy of the preliminary prospectus relating to the
offering may be obtained from BofA Merrill Lynch, NC1-004-03-43,
200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department or by email at
dg.prospectus_requests@baml.com; Cowen and Company, LLC, c/o
Broadridge Financial Services, Attention: Prospectus Department,
1155 Long Island Avenue, Edgewood,
NY 11717 or by telephone at (631) 274-2806; or Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800)
747-3924 or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and other federal securities laws. Any statements
contained herein that do not describe historical facts, including,
but not limited to, statements regarding the size and completion of
the proposed offering, are forward-looking statements that involve
risks and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, the risks
identified in Audentes' filings with the SEC, the prospectus
related to the offering, and subsequent filings with the SEC.
Any of these risks and uncertainties could materially and
adversely affect Audentes' results of operations, which would, in
turn, have a significant and adverse impact on Audentes' stock
price. Audentes cautions you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made. Audentes undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date they were made or to reflect
the occurrence of unanticipated events.
Audentes Contacts:
Investor Contact:
Thomas Soloway
415-818-1040
ir@audentestx.com
Media Contact:
Jeffrey Gruis
415-818-1015
media@audentestx.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-proposed-public-offering-of-common-stock-300440343.html
SOURCE Audentes Therapeutics, Inc.